Jiahao Wang
A5101877979- Cancer Genomics and Diagnostics
- Cancer Immunotherapy and Biomarkers
- Immune Cell Function and Interaction
- vaccines and immunoinformatics approaches
- Cancer, Lipids, and Metabolism
- Liver Disease Diagnosis and Treatment
- Organic Electronics and Photovoltaics
- Bladder and Urothelial Cancer Treatments
- Nutrition and Health in Aging
- Nutritional Studies and Diet
- Force Microscopy Techniques and Applications
- Nutrition, Genetics, and Disease
- Molecular Junctions and Nanostructures
Xi'an Jiaotong University
2025
Xuzhou Medical College
2024
Center for Excellence in Molecular Cell Science
2023
Chinese Academy of Sciences
2023
University of Chinese Academy of Sciences
2023
Amines are one of the most ubiquitous functional groups in molecular junctions; however, exact regulation charge transport through protonation state an amine group junction backbone remains elusive. We address this question here by designing a diphenylamine and experimentally investigating how central affects transport. Our ultraviolet-visible spectroscopy measurements demonstrate reaction compound presence either trifluoroacetic acid or HCl, we observe consistent trend modestly increased...
Abstract Purpose: PD-1 blockade plus chemotherapy has become the new standard of care in patients with untreated advanced non–small cell lung cancer (NSCLC), whereas predictive biomarkers remain undetermined. Experimental Design: We integrated clinical, genomic, and survival data 427 NSCLC treated first-line or from two phase III trials (CameL CameL-sq) investigated prognostic value HLA class I evolutionary divergence (HED). Results: High HED could predict significantly improved objective...
Bladder carcinoma is a type of urological tumor with high risks recurrence and progression. The triglyceride-glucose (TyG) index has demonstrated significant promise as prognostic marker for metabolic health in different types cancer. Further research needed to explore the relationships among non-muscle-invasive bladder cancer (NMIBC), TyG index, its importance. Purpose this preliminary assess predictive significance progression risk NMIBC patients.
<p>Supplementary Materials</p>
<div>Abstract<p>Purpose: PD-1 blockade plus chemotherapy has become the new standard of care in patients with untreated advanced non-small-cell lung cancer (NSCLC), whereas predictive biomarkers remain undetermined. Patients and Methods: We integrated clinical, genomic survival data 427 NSCLC treated first-line or from two phase 3 trials (CameL CameL-sq) investigated prognostic value HLA class I evolutionary divergence (HED). Results: High HED could predict significantly improved...
<p>Supplementary Materials</p>
<div>AbstractPurpose:<p>PD-1 blockade plus chemotherapy has become the new standard of care in patients with untreated advanced non–small cell lung cancer (NSCLC), whereas predictive biomarkers remain undetermined.</p>Experimental Design:<p>We integrated clinical, genomic, and survival data 427 NSCLC treated first-line PD-1 or from two phase III trials (CameL CameL-sq) investigated prognostic value HLA class I evolutionary divergence...
<div>Abstract<p>Purpose: PD-1 blockade plus chemotherapy has become the new standard of care in patients with untreated advanced non-small-cell lung cancer (NSCLC), whereas predictive biomarkers remain undetermined. Patients and Methods: We integrated clinical, genomic survival data 427 NSCLC treated first-line or from two phase 3 trials (CameL CameL-sq) investigated prognostic value HLA class I evolutionary divergence (HED). Results: High HED could predict significantly improved...
<p>Supplementary Materials</p>
<p>Supplementary Materials</p>
<div>AbstractPurpose:<p>PD-1 blockade plus chemotherapy has become the new standard of care in patients with untreated advanced non–small cell lung cancer (NSCLC), whereas predictive biomarkers remain undetermined.</p>Patients and Methods:<p>We integrated clinical, genomic, survival data 427 NSCLC treated first-line PD-1 or from two phase III trials (CameL CameL-sq) investigated prognostic value HLA class I evolutionary divergence (HED).</p>Results:<p>High...
<p>Supplementary Materials</p>
<p>Supplementary Materials</p>